313 related articles for article (PubMed ID: 26346796)
21. Treatment effects of immunomodulatory therapies at different stages of multiple sclerosis in short-term trials.
Bates D
Neurology; 2011 Jan; 76(1 Suppl 1):S14-25. PubMed ID: 21205678
[TBL] [Abstract][Full Text] [Related]
22. [Immunomodulatory therapy in multiple sclerosis].
Csépány T; Bereczki D
Ideggyogy Sz; 2004 Nov; 57(11-12):401-16. PubMed ID: 15662768
[TBL] [Abstract][Full Text] [Related]
23. Pharmacogenomics strategies to optimize treatments for multiple sclerosis: Insights from clinical research.
Grossman I; Knappertz V; Laifenfeld D; Ross C; Zeskind B; Kolitz S; Ladkani D; Hayardeny L; Loupe P; Laufer R; Hayden M
Prog Neurobiol; 2017 May; 152():114-130. PubMed ID: 26952809
[TBL] [Abstract][Full Text] [Related]
24. Impact of disease-modifying therapies on brain and spinal cord atrophy in multiple sclerosis.
Rudick RA
J Neuroimaging; 2004 Jul; 14(3 Suppl):54S-64S. PubMed ID: 15228760
[TBL] [Abstract][Full Text] [Related]
25. Disease-modifying drugs for the early treatment of multiple sclerosis.
Flachenecker P
Expert Rev Neurother; 2004 May; 4(3):455-63. PubMed ID: 15853542
[TBL] [Abstract][Full Text] [Related]
26. Clinical trials of multiple sclerosis therapies: improvements to demonstrate long-term patient benefit.
Carroll WM
Mult Scler; 2009 Aug; 15(8):951-8. PubMed ID: 19465446
[TBL] [Abstract][Full Text] [Related]
27. Neurodegeneration and clinical relevance for early treatment in multiple sclerosis.
Rieckmann P
Int MS J; 2005 Aug; 12(2):42-51. PubMed ID: 16417814
[TBL] [Abstract][Full Text] [Related]
28. New options for early treatment of multiple sclerosis.
Tintoré M
J Neurol Sci; 2009 Feb; 277 Suppl 1():S9-S11. PubMed ID: 19200870
[TBL] [Abstract][Full Text] [Related]
29. Neuronal injury in chronic CNS inflammation.
Zindler E; Zipp F
Best Pract Res Clin Anaesthesiol; 2010 Dec; 24(4):551-62. PubMed ID: 21619866
[TBL] [Abstract][Full Text] [Related]
30. Fingolimod versus interferon beta/glatiramer acetate after natalizumab suspension in multiple sclerosis.
Iaffaldano P; Lucisano G; Pozzilli C; Brescia Morra V; Ghezzi A; Millefiorini E; Patti F; Lugaresi A; Zimatore GB; Marrosu MG; Amato MP; Bertolotto A; Bergamaschi R; Granella F; Coniglio G; Tedeschi G; Sola P; Lus G; Ferrò MT; Iuliano G; Corea F; Protti A; Cavalla P; Guareschi A; Rodegher M; Paolicelli D; Tortorella C; Lepore V; Prosperini L; Saccà F; Baroncini D; Comi G; Trojano M;
Brain; 2015 Nov; 138(Pt 11):3275-86. PubMed ID: 26362907
[TBL] [Abstract][Full Text] [Related]
31. Effect of fingolimod on diffuse brain tissue damage in relapsing-remitting multiple sclerosis patients.
De Stefano N; Tomic D; Radue EW; Sprenger T; Meier DP; Häring D; Sormani MP
Mult Scler Relat Disord; 2016 May; 7():98-101. PubMed ID: 27237768
[TBL] [Abstract][Full Text] [Related]
32. Emerging therapies in multiple sclerosis.
Farrell R; Heaney D; Giovannoni G
Expert Opin Emerg Drugs; 2005 Nov; 10(4):797-816. PubMed ID: 16262563
[TBL] [Abstract][Full Text] [Related]
33. Canadian treatment optimization recommendations (TOR) as a predictor of disease breakthrough in patients with multiple sclerosis treated with interferon beta-1a: analysis of the PRISMS study.
Freedman MS; Forrestal FG
Mult Scler; 2008 Nov; 14(9):1234-41. PubMed ID: 18632774
[TBL] [Abstract][Full Text] [Related]
34. Natural history of multiple sclerosis: have available therapies impacted long-term prognosis?
Trojano M; Paolicelli D; Tortorella C; Iaffaldano P; Lucchese G; Di Renzo V; D'Onghia M
Neurol Clin; 2011 May; 29(2):309-21. PubMed ID: 21439443
[TBL] [Abstract][Full Text] [Related]
35. Early treatment and dose optimisation BENEFIT and BEYOND.
Hartung HP
J Neurol; 2005 Sep; 252 Suppl 3():iii44-iii50. PubMed ID: 16170501
[TBL] [Abstract][Full Text] [Related]
36. [Disease modifying therapies in multiple sclerosis].
Fukaura H
Nihon Rinsho; 2014 Nov; 72(11):2015-22. PubMed ID: 25518387
[TBL] [Abstract][Full Text] [Related]
37. Natalizumab therapy for highly active pediatric multiple sclerosis.
Kornek B; Aboul-Enein F; Rostasy K; Milos RI; Steiner I; Penzien J; Hellwig K; Pitarokoili K; Storm van's Gravesande K; Karenfort M; Blaschek A; Meyer A; Seidl R; Debelic D; Vass K; Prayer D; Kristoferitsch W; Bayas A
JAMA Neurol; 2013 Apr; 70(4):469-75. PubMed ID: 23420110
[TBL] [Abstract][Full Text] [Related]
38. Therapeutic approaches to disease modifying therapy for multiple sclerosis in adults: an Australian and New Zealand perspective: part 1 historical and established therapies. MS Neurology Group of the Australian and New Zealand Association of Neurologists.
Broadley SA; Barnett MH; Boggild M; Brew BJ; Butzkueven H; Heard R; Hodgkinson S; Kermode AG; Lechner-Scott J; Macdonell RA; Marriott M; Mason DF; Parratt J; Reddel SW; Shaw CP; Slee M; Spies J; Taylor BV; Carroll WM; Kilpatrick TJ; King J; McCombe PA; Pollard JD; Willoughby E;
J Clin Neurosci; 2014 Nov; 21(11):1835-46. PubMed ID: 24993135
[TBL] [Abstract][Full Text] [Related]
39. [The interferon beta therapy after the first clinical episode of demyelination in multiple sclerosis].
Demina TL; Khachanova NV; Davydovskaia MV
Zh Nevrol Psikhiatr Im S S Korsakova; 2006; 106(3):15-9. PubMed ID: 16608106
[TBL] [Abstract][Full Text] [Related]
40. Treatment options for patients with multiple sclerosis who have a suboptimal response to interferon-β therapy.
Freedman MS
Eur J Neurol; 2014 Mar; 21(3):377-87, e18-20. PubMed ID: 24237582
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
